Stemline Therapeutics (NASDAQ:STML) released its earnings results on Thursday. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.06), Fidelity Earnings reports.
NASDAQ:STML opened at $13.20 on Friday. Stemline Therapeutics has a 1 year low of $12.60 and a 1 year high of $20.55. The firm has a market capitalization of $462.77 million, a price-to-earnings ratio of -4.49 and a beta of 0.58.
A number of analysts have issued reports on STML shares. BidaskClub raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 19th. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 16th. ValuEngine raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 14th. Finally, HC Wainwright set a $38.00 target price on Stemline Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 10th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Stemline Therapeutics presently has an average rating of “Buy” and a consensus price target of $30.00.
TRADEMARK VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/10/stemline-therapeutics-stml-announces-earnings-results.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Read More: How is the S&P 500 index different from the DJIA?
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.